S
Subhankar Chatterjee
Researcher at Rajendra Institute of Medical Sciences
Publications - 73
Citations - 2239
Subhankar Chatterjee is an academic researcher from Rajendra Institute of Medical Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 63 publications receiving 1069 citations. Previous affiliations of Subhankar Chatterjee include R. G. Kar Medical College and Hospital.
Papers
More filters
Journal ArticleDOI
Psychosocial impact of COVID-19.
Souvik Dubey,Payel Biswas,Ritwik Ghosh,Subhankar Chatterjee,Mahua Jana Dubey,Subham Chatterjee,Durjoy Lahiri,Carl J. Lavie +7 more
TL;DR: The psychosocial aspects of older people, their caregivers, psychiatric patients and marginalized communities are affected by this pandemic in different ways and need special attention.
Journal ArticleDOI
Impact of COVID -19 on children: special focus on the psychosocial aspect.
TL;DR: Parents, pediatricians, psychologists, social workers, hospital authorities, government and non-governmental organizations have important roles to play to mitigate the psychosocial ill-effects of COVID-19 on children and adolescents.
Journal ArticleDOI
COVID-19 and addiction.
Mahua Jana Dubey,Ritwik Ghosh,Subham Chatterjee,Payel Biswas,Subhankar Chatterjee,Souvik Dubey +5 more
TL;DR: The intricate bi-directional relationship between COVID-19 and addiction is analyzed, showing surge of addictive behaviors (both new and relapse) including behavioral addiction in this period and people with SUD are at greater risk of worse CO VID-19 outcome.
Journal ArticleDOI
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Manasvi Gupta,Colin Blumenthal,Subhankar Chatterjee,Dhrubajyoti Bandyopadhyay,Vardhmaan Jain,Carl J. Lavie,Salim S. Virani,Kausik K. Ray,Wilbert S. Aronow,Raktim K. Ghosh +9 more
TL;DR: New options now exist for the prevention of atherosclerosis in patients that are not optimized on statin therapy and newly approved non-statin-based therapies such as ezetimibe, icosapent ethyl (IPE), and bempedoic acid are discussed.
Journal ArticleDOI
COVID-19: the endocrine opportunity in a pandemic.
Subhankar Chatterjee,Ritwik Ghosh,Payel Biswas,Souvik Dubey,Rishi Tuhin Guria,Chandra Bhushan Sharma,Sanjay Kalra +6 more
TL;DR: How various endocrinological disorders influence the dynamics of COVID-19 and vice versa is examined and the clinical guidelines to be adopted in practice of endocrinology in this trying time are reviewed.